[go: up one dir, main page]

PE20021013A1 - Dihidropirimidinas-5-ciano sustituidos como agentes antiproliferativos - Google Patents

Dihidropirimidinas-5-ciano sustituidos como agentes antiproliferativos

Info

Publication number
PE20021013A1
PE20021013A1 PE2002000232A PE2002000232A PE20021013A1 PE 20021013 A1 PE20021013 A1 PE 20021013A1 PE 2002000232 A PE2002000232 A PE 2002000232A PE 2002000232 A PE2002000232 A PE 2002000232A PE 20021013 A1 PE20021013 A1 PE 20021013A1
Authority
PE
Peru
Prior art keywords
cyane
alkyl
cycloalkyl
substituted
dihydropyrimidines
Prior art date
Application number
PE2002000232A
Other languages
English (en)
Inventor
Spencer David Kimball
Louis J Lombardo
Hai-Yun Xiao
Robert Joseph Schmidt
David Kent Williams
David B Rawlins
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20021013A1 publication Critical patent/PE20021013A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DE DIHIDROPIRIMIDINA CIANO SUBSTITUIDOS DE FORMULA I DONDE R1 ES H, ALQUILO, CICLOALQUILO: R2 Y R3 SON H, ALQUILO, ARILO HETEROARILO, ARILALQUILO, CICLOALQUILO, ENTRE OTROS; R2 Y R3 JUNTOS FORMAN UN ANILLO HETEROCICLICO, CARBOCICLICLO; R4 ES ALQUILO, ARILALQUILO, CICLOALQUILALQUILO, ENTRE OTROS; R5 Y R6 SON H, ALQUILO, CICLOALQUILO ENTRE OTROS; Z ES O, S, NR8; R8 ES H, CN, SULFONAMIDO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS ESTER 1-ETILICO DEL ACIDO 5-CIANO-3,6-DIHIDRO-4-METIL-6-(3-NITROFENIL)-2-TIOXO-1-(2H)-PIRIMIDINCARBOXILICO, ESTER 1-ETILICO DEL ACIDO 5-CIANO-3,6-DIHIDRO-4-METIL-6-(3-NITROFENIL)-2-OXO-1-(2H)-PIRIMIDINCARBOXILICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. LOS COMPUESTOS MENCIONADOS INDUCEN INTERRUPCION MITOTICA Y SON UTILES COMO AGENTES ANTICANCERIGENOS
PE2002000232A 2001-03-29 2002-03-25 Dihidropirimidinas-5-ciano sustituidos como agentes antiproliferativos PE20021013A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27995601P 2001-03-29 2001-03-29

Publications (1)

Publication Number Publication Date
PE20021013A1 true PE20021013A1 (es) 2002-11-10

Family

ID=23071059

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000232A PE20021013A1 (es) 2001-03-29 2002-03-25 Dihidropirimidinas-5-ciano sustituidos como agentes antiproliferativos

Country Status (26)

Country Link
US (1) US6809102B2 (es)
EP (1) EP1373221A4 (es)
JP (1) JP2005504725A (es)
KR (1) KR20030086327A (es)
CN (1) CN1507435A (es)
AR (1) AR034585A1 (es)
BG (1) BG108180A (es)
BR (1) BR0208405A (es)
CA (1) CA2442482A1 (es)
CZ (1) CZ20032645A3 (es)
EE (1) EE200300474A (es)
HR (1) HRP20030875A2 (es)
HU (1) HUP0400350A3 (es)
IL (1) IL157441A0 (es)
IS (1) IS6967A (es)
MX (1) MXPA03008634A (es)
NO (1) NO20034300L (es)
PE (1) PE20021013A1 (es)
PL (1) PL373759A1 (es)
RU (1) RU2003130961A (es)
SK (1) SK11062003A3 (es)
TW (1) TWI228416B (es)
UY (1) UY27232A1 (es)
WO (1) WO2002079149A2 (es)
YU (1) YU75803A (es)
ZA (2) ZA200306648B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900214B2 (en) * 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
CA2469801C (en) * 2001-12-11 2011-06-21 Kyowa Hakko Kogyo Co., Ltd. Thiadiazoline derivative
AR050920A1 (es) * 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
JP3947758B2 (ja) * 2003-03-07 2007-07-25 アストラゼネカ アクチボラグ 新規縮合ヘテロサイクル及びその使用
JP4676881B2 (ja) 2003-04-18 2011-04-27 協和発酵キリン株式会社 M期キネシン阻害剤
WO2004111024A1 (ja) * 2003-06-10 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. チアジアゾリン誘導体
WO2005007124A2 (en) 2003-07-23 2005-01-27 Bristol-Myers Squibb Company Substituted dihydropyrimidine inhibitors of calcium channel function
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
WO2005037799A1 (en) * 2003-10-16 2005-04-28 Cytokinetics, Inc. Compounds, compositions, and methods
RU2007106552A (ru) * 2004-07-22 2008-08-27 Астразенека Аб (Se) Конденсированные пиримидоны, пригодные для лечения и предотвращения злокачественного новообразования
RU2447077C2 (ru) * 2004-08-18 2012-04-10 Астразенека Аб Энантиомеры выбранных конденсированных пиримидинов и их применение для лечения и предотвращения злокачественного новообразования
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
WO2006060737A2 (en) * 2004-12-03 2006-06-08 Takeda San Diego, Inc. Mitotic kinesin inhibitors
EP1870404A4 (en) * 2005-03-22 2010-07-14 Kyowa Hakko Kirin Co Ltd MEANS FOR THE TREATMENT OF A HEMATOPOIETIC TUMOR
AU2006225636A1 (en) * 2005-03-22 2006-09-28 Fujifilm Corporation Therapeutic agent for solid tumor
EP1908755A4 (en) * 2005-06-24 2009-06-24 Kyowa Hakko Kirin Co Ltd THERAPEUTIC AGENT AGAINST RESTENOSIS
DE102006002065B4 (de) * 2006-01-16 2007-11-29 Infineon Technologies Austria Ag Kompensationsbauelement mit reduziertem und einstellbarem Einschaltwiderstand
CN110464722B (zh) * 2019-06-06 2023-05-23 暨南大学 一类小分子化合物或其药学上可接受的盐在制备抗肿瘤转移药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211198B1 (en) 1993-04-05 2001-04-03 Synaptic Pharmaceutical Corporation Dihydropyridines and new uses thereof
HUT77941A (hu) 1994-11-16 1998-12-28 Synaptic Pharmaceutical Corporation Dihidropirimidinszármazékok és ezek alkalmazása
WO1997017969A1 (en) 1995-11-16 1997-05-22 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
EP1021185A4 (en) 1996-05-16 2005-09-07 Synaptic Pharma Corp DIHYDROPYRIMIDINES AND THEIR JOBS
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
CA2294349A1 (en) 1997-06-18 1998-12-23 Michael A. Patane Alpha 1aadrenergic receptor antagonists
US6080760A (en) 1997-06-18 2000-06-27 Merck & Co., Inc. Alpha 1A adrenergic receptor antagonists
WO1999025345A1 (en) 1997-11-14 1999-05-27 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
WO1999050440A2 (en) 1998-04-01 1999-10-07 Yale University Method to identify modulators of survivin - tubulin interaction
US6300084B1 (en) 1998-10-08 2001-10-09 The Regents Of The University Of California Anti-mitotic agent screening process
AUPQ171999A0 (en) 1999-07-20 1999-08-12 University Of Sydney, The Neurotropic virus transport
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
US6617115B1 (en) 1999-10-27 2003-09-09 Cytokinetics, Inc. Methods of screening for modulators of cell proliferation
DE60028227T2 (de) 1999-10-27 2007-03-29 Cytokinetics, Inc., South San Francisco Chinazolinone benutzende verfahren und zusammenstellungen
US6284480B1 (en) 2000-04-03 2001-09-04 Cytokinetics, Inc. Antifungal assay
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases

Also Published As

Publication number Publication date
AR034585A1 (es) 2004-03-03
WO2002079149A2 (en) 2002-10-10
NO20034300L (no) 2003-11-07
HUP0400350A2 (hu) 2005-01-28
HUP0400350A3 (en) 2005-06-28
EP1373221A2 (en) 2004-01-02
PL373759A1 (en) 2005-09-05
YU75803A (sh) 2006-05-25
ZA200307320B (en) 2004-12-20
CZ20032645A3 (cs) 2004-06-16
RU2003130961A (ru) 2005-04-10
US20030008888A1 (en) 2003-01-09
BG108180A (en) 2004-09-30
CA2442482A1 (en) 2002-10-10
EE200300474A (et) 2003-12-15
ZA200306648B (en) 2004-11-26
HRP20030875A2 (en) 2004-08-31
US6809102B2 (en) 2004-10-26
KR20030086327A (ko) 2003-11-07
WO2002079149A3 (en) 2003-02-27
BR0208405A (pt) 2004-03-30
UY27232A1 (es) 2002-11-29
JP2005504725A (ja) 2005-02-17
CN1507435A (zh) 2004-06-23
NO20034300D0 (no) 2003-09-26
IL157441A0 (en) 2004-03-28
SK11062003A3 (sk) 2004-08-03
EP1373221A4 (en) 2004-09-29
IS6967A (is) 2003-09-24
TWI228416B (en) 2005-03-01
MXPA03008634A (es) 2003-12-08

Similar Documents

Publication Publication Date Title
PE20021013A1 (es) Dihidropirimidinas-5-ciano sustituidos como agentes antiproliferativos
PE20010854A1 (es) USO DE DERIVADOS DE PIRIMIDINA 4 SUSTITUIDOS COMO ANTAGONISTAS DE LOS RECEPTORES DE GLUTAMATO mGluR1
PE20050525A1 (es) Derivados de pirazol sustituido y compuestos relacionados como antagonistas del receptor de bradiquinina b1
AR051202A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
PE20040071A1 (es) Indazoles substituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
CO5611147A2 (es) Derivados de nicotinamida utiles como inhibidores p38
PE20020753A1 (es) Heteroaromaticos fusionados como activadores de la glucoquinasa
AR036107A1 (es) Derivados de 6-fenilpirrolpirimidindiona, antagonista de los receptores a2 de la adenosina, particularmente del subtipo a2, de aplicacion en la prevencion de la degranulacion de los mastocitos; composiciones farmaceuticas formuladas con dichos compuestos y uso de los mismos en la preparacion de medi
AR038341A1 (es) Compuestos que son agonistas de receptores alfa-1 preferentemente agonistas de receptores alfa-1a/l
AR048642A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
CO5580778A2 (es) Derivados de lactama como antagonistas para receptores 11cby humanos
MXPA04003610A (es) Analogos de himbacina como antagonistas del receptor de trombina.
PE20010930A1 (es) Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelina duales
CO5700754A2 (es) Derivados de piperazina y su uso en el tratamiento de enfermedades neurologicas y psiquiatricas
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
AR060658A1 (es) Derivados de diceto-piperazina y piperidina como agentes antivirales
PE20040687A1 (es) Quinolinas sustituidas como antagonistas del receptor ccr5
AR045747A1 (es) Derivados de 2,4 di (hetero)-arilamino-pirimidina como zap-70 inhibidores
AR051092A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
AR053770A1 (es) Pirimidinas como antagonistas del receptor de prostaglandina d2. composiciones farmaceuticas.
PE20040772A1 (es) Composicion y actividad antiviral de derivados de piperazina azaindoloxoaceticos
AR044614A1 (es) Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4)
NO20063380L (no) Triazolderivater som vasopressinantagonister

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed